Skip to main content
. 2020 Apr 21;35(4):929–938. doi: 10.1093/humrep/deaa029

Figure 2.

Figure 2

Overall survival in women with breast cancer who underwent FP at six Swedish hospitals from 1995 to 2017 and in control women unexposed to FP. Left upper panel: a comparison of overall survival with Kaplan–Meier estimates in women who underwent FP with or without hormonal stimulation and that in women unexposed to fertility preservation (n = 610). Right panel: a comparison of overall survival with Kaplan–Meier estimates in women who underwent FP with COS and in women who were unexposed top COS (n = 610). Left lower panel: a comparison of OS with Kaplan–Meier estimates in women who underwent COS with (Letrozole) or without (No Letrozole) concurrent use of letrozole (n = 380). The use of letrozole alongside gonadotropins in cycles aimed at FP was implemented in Sweden in 2010.